CD8A and non-small cell lung carcinoma: In a study of patients with non-small cell lung cancer (NSCLC) receiving PD-(L)1 inhibitor treatment, fewer circulating CD8 T cells prior to ICI was associated with durable clinical benefit (DCB) (accuracy = 70%) [18].